Get the Stockscreener App
96.38
1.35%
1.28
After Hours:
96.38
Blueprint Medicines Corp stock is traded at $96.38, with a volume of 327.94K.
It is up +1.35% in the last 24 hours and up +15.56% over the past month.
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
See More
Previous Close:
$95.10
Open:
$95.7
24h Volume:
327.94K
Relative Volume:
0.52
Market Cap:
$6.04B
Revenue:
$434.41M
Net Income/Loss:
$-128.05M
P/E Ratio:
-10.49
EPS:
-9.19
Net Cash Flow:
$-250.52M
1W Performance:
+2.37%
1M Performance:
+15.56%
6M Performance:
-4.17%
1Y Performance:
+40.74%
1-Day Range:
$94.84
$97.98
1-Week Range:
$91.78
$97.98
52-Week Range:
$68.28
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Name
Blueprint Medicines Corp
Sector
Industry
Phone
617-374-7580
Address
45 SIDNEY STREET, CAMBRIDGE, MA
Compare BPMC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
96.38 | 6.04B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | JP Morgan | Overweight |
| Oct-24-24 | Initiated | UBS | Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| May-06-24 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Oct-27-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-21-23 | Reiterated | Needham | Buy |
| Jul-31-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-05-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Jan-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Needham | Buy |
| Nov-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-14-22 | Initiated | Berenberg | Buy |
| Jul-08-22 | Initiated | Oppenheimer | Outperform |
| Jun-27-22 | Initiated | Wells Fargo | Underweight |
| Jun-10-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-01-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-01-22 | Initiated | Citigroup | Neutral |
| Feb-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-25-22 | Upgrade | Stifel | Hold → Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-21 | Resumed | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Hold |
| Nov-02-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-30-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Equal Weight |
| Mar-17-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Nov-06-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-22-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Sep-12-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-29-19 | Initiated | Piper Jaffray | Neutral |
| Aug-15-19 | Resumed | Raymond James | Mkt Perform |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-23-19 | Resumed | Goldman | Buy |
| Apr-03-19 | Initiated | Morgan Stanley | Overweight |
| Sep-25-18 | Initiated | Leerink Partners | Outperform |
| Dec-11-17 | Reiterated | Goldman | Buy |
View All
Blueprint Medicines Corp Stock (BPMC) Latest News
Fmr LLC Sells 316,913 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 5,132 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Alkeon Capital Management LLC - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Citigroup Inc. - MarketBeat
Blueprint Medicines (FRA:2L9) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
Intech Investment Management LLC Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Massachusetts Financial Services Co. MA Has $23.33 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Pitcairn Co. Has $954,000 Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Invests $6.47 Million in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (FRA:2L9) EPS without NRI : €-4.43 (TTM As of Sep. 2024) - GuruFocus.com
Blueprint Medicines (FRA:2L9) Revenue per Share : €6.33 (TTM As of Sep. 2024) - GuruFocus.com
Blueprint Medicines (FRA:2L9) Operating Cash Flow per Share : €-3.56 (TTM As of Sep. 2024) - GuruFocus.com
Algert Global LLC Increases Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Eagle Asset Management Inc. - MarketBeat
Blueprint Medicines director Coats sells $1.87 million in stock - Investing.com India
Principal Financial Group Inc. Decreases Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines director Coats sells $1.87 million in stock By Investing.com - Investing.com Canada
What is Zacks Research's Forecast for BPMC FY2024 Earnings? - MarketBeat
Segall Bryant & Hamill LLC Buys 14,668 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (LTS:0HOJ) Enterprise Value : $5,746.9 Mil (As of Nov. 20, 2024) - GuruFocus.com
Blueprint Medicines initiated with an Overweight at JPMorgan - MSN
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Cut by Victory Capital Management Inc. - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines’ (BPMC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World
Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at Needham & Company LLC - MarketBeat
HC Wainwright Reiterates Buy Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation - MSN
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Yahoo Finance
Key Takeaways From Blueprint Medicines Analyst Ratings - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Now Covered by JPMorgan Chase & Co. - MarketBeat
Mastocytosis Treatment Market Forecasted for Major Expansion - openPR
Entropy Technologies LP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Raised by US Bancorp DE - MarketBeat
M&G Plc Makes New $9.10 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - MarketBeat
Blueprint Medicines' SWOT analysis: stock soars on Ayvakit success, pipeline potential - Investing.com
Blueprint Medicines discloses CDK2 inhibitors for cancer - BioWorld Online
Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve
Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World
Q1 Earnings Forecast for BPMC Issued By HC Wainwright - MarketBeat
Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given “Buy” Rating at Needham & Company LLC - Defense World
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales By Investing.com - Investing.com South Africa
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com
Blueprint Medicines Corp Stock (BPMC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):